The biotech specialist Polymun is helping out with lipid nanoparticles in order to combat the coronavirus. Simply put, these lipid nanoparticles bring the substances of the anti-coronavirus vaccine to the cells. This involves an RNA vaccine whose mechanism of action is based on ribonucleic acid. A protein is produced from the RNA which triggers an immune response. For this purpose, the RNA from the vaccine actually has to reach the cells, because otherwise they would already be broken down by the body. This is where the lipid nanoparticles of Polymun play a role because they prevent this from taking place.
Due to the expected high level of demand, the Austrian biotech company with about 90 employees wants to realise the technologies it developed in collaboration with partners or build up the manufacturing technology globally at different production sites. Polymun, founded in 1992, is a private, family-owned company. The core competencies are in the development and production of biopharmaceuticals as well as in the innovative liposome technology.
Read on and find out more about research and development in Austria.